AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not ...
Zacks Investment Research on MSN1d
AZN's Imfinzi Gets EU Nod for Limited-Stage Small-Cell Lung CancerAstraZeneca AZN recently announced that the European Commission has approved its blockbuster cancer drug Imfinzi (durvalumab) ...
Clinical Trials Arena on MSN8d
AstraZeneca reports positive outcomes from trial of ImfinziThis perioperative approach with Imfinzi underscores our commitment to moving into earlier stages of cancer where novel ...
Imfinzi has been approved in the European Union as monotherapy for the treatment of adults with limited-stage small cell ...
AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in ...
Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...
Approval based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo ...
AstraZeneca Plc (NASDAQ:AZN) released high-level results from the MATTERHORN Phase 3 trial evaluating Imfinzi (durvalumab) as ...
AstraZeneca's eneboparatide met its Phase 3 trial goal for chronic hypoparathyroidism, while the EU approved Imfinzi for ...
AstraZeneca (AZ) has shared positive results from a late-stage trial of its Imfinzi (durvalumab)-based perioperative regimen ...
Astra will buy EsoBiotec for up to £770m comprised of an initial £327m payment and another £443m in the future if it hits ...
The safety profile for Imfinzi was generally manageable and consistent with the known profile of this medicine.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback